ConnexPay launches revolutionary real-time B2B payments in Europe with GBP, EUR currencies
18.7.2023 14:00:00 EEST | Business Wire | Press release
ConnexPay, the first and only payments technology company that offers a fully integrated payments acceptance and payment issuance solution inside a single platform, has expanded upon an already impressive global footprint with the launch of British Pounds (GBP) and Euros (EUR) currencies. The company has operated for years in the European market, but this release allows European companies the flexibility to receive and send payments in their native currencies.
Despite the complexity of the payments landscape, ConnexPay’s core solution is extremely smart and user-friendly. The all-in-one platform allows merchants to have immediate access to incoming customer payments, which they can then use in real time to fund virtual cards to pay suppliers. With ConnexPay, businesses no longer have to wait for incoming payments to clear before accessing those funds, a process that could take anywhere from days to weeks, causing cashflow problems for a company’s entire supply chain. In addition, ConnexPay’s payments solution integrates fraud prevention and chargeback management plus a fully-featured reporting and analytics suite – all inside a single platform with one contract, one reconciliation, and one team.
The company already has a number of international customers who now add the ability to transact in GBP and EUR. Enabling them to issue in multiple currencies globally is vital to these businesses, and there are a host of additional global companies that will be implementing ConnexPay’s solution and going live this month.
Bob Kaufman, Founder and CEO at ConnexPay, said: “After five years building our solution to great success in North America, we’re excited to launch native currencies in Europe knowing that our solution is fit for purpose, global in scope and simply connects payments. We have worked closely with our key partners to ensure that what we are delivering is exactly what the market needs. ConnexPay is the only company in the world that provides an end-to-end payments solution all inside a single platform.”
He added: “We have shown our international customers that having both card issuing and acceptance as a single solution can significantly increase efficiencies and lower the costs of both accepting incoming payments and making cross-border payments. I’m thrilled to already have some innovative customers on board with the ability to issue in more currencies, helping these companies scale, as we scale, and continuing to work with them to bring their services to customers across the globe.”
ConnexPay currently processes billions in volume and recently received a $110 million growth equity investment led by FTV Capital, a sector-focused investor with more than two decades of experience in payments and financial services. The investment from FTV Capital has been a major factor in enabling ConnexPay to expand globally with a revolutionary product and the infrastructure to support rapid growth. In the last 12 months alone, ConnexPay has seen revenue increase by 500% and expects to double revenue this year.
To learn more visit: https://connexpay.com/
About ConnexPay
ConnexPay is the first and only company to bring together the two sides of the payment process — payments acceptance and virtual payments issuing — into a single platform with one contract and one reconciliation. The flexibility of this technology allows clients to adopt the full end-to-end acquiring and issuing solution or leverage ConnexPay’s innovative intelligent routing issuing-only platform.
Although ConnexPay started its journey with a focus on the travel and tourism space, ConnexPay’s solutions are applicable across a broad spectrum of corporate payment use cases. The platform is well suited for corporate disbursements like insurance and warranty claims, loyalty and rewards payouts as well as corporate procurements like media/advertising buys and ticketing.
The company’s technology simplifies an antiquated workflow, eliminates the need for pre-funded accounts, reduces supplier risk and the cost of accepting card payments while safeguarding consumer spend. Learn more at www.connexpay.com and follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230718177919/en/
Contact information
Ben Redman, SkyParlour
ben@skyparlour.com
+44 (0)330 043 1315
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 16:02:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community. “At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinic
First Cessna Citation CJ4 Gen3 Advances Toward Entry Into Service as First Production Unit Rolls out of the Factory20.10.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently celebrated the rollout of the first production unit of the Cessna Citation CJ4 Gen3, an important milestone as the aircraft advances toward entry into service. The rollout represents Textron Aviation's continued investment in the light jet lineup, bringing Garmin G3000 PRIME avionics, Garmin Emergency Autoland and other customer-driven enhancements to the proven Citation CJ4 platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020982419/en/ First Cessna Citation CJ4 Gen3 advances toward entry into service as first production unit rolls out of the factory. (Photo credit: Textron Aviation) “This rollout is a visible result of the care, precision and teamwork that move an aircraft from design intent to a production-ready airplane,” said Eric Cardinali, senior vice president, Manufacturing Operations. “For our manufacturing teams, it represents the discipl
ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 15:00:00 EEST | Press release
ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehensive foundation that captures the relationships between processes, people, systems, risks and controls. Built on a comprehensive Digital Twin of the Organization that connects how work is designed with the execution data that sits around it, ARIS provides this critical layer of Process Context from more than 30 years of enterprise knowledge and experience, something new entrants to the space are struggling to replicate. The importan
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 15:00:00 EEST | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i
Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma. Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
